Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: A phase II study

Chemotherapy

Volumn 54, Issue 1, 2007, Pages 54-62

  Kim, Hawk ^a   Park, Jae Hoo ^a   Shin, Su Jin ^a   Kim, Mee Ja ^a   Bang, Sung Jo ^a   Park, Neung Hwa ^a   Nah, Yang Won ^a   Nam, Chang Woo ^a   Joo, Kwang Ro ^b   Min, Young Joo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Doxifluridine; Fixed dose rate infusion; Gemcitabine; Pancreatic cancer

Indexed keywords

DOXIFLURIDINE; FOLINIC ACID; GEMCITABINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDICAL RESEARCH; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PATHOLOGY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UREMIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 37348999691     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112417     Document Type: Article

References (31)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
4. Cascinu S, Frontini L, Labianca R, Catalano V, Barni S, Graiff C, Picone G, Farinati E, Zonato S, Pessi MA, Curti C, Catalano G: A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2000;11:1309-1311.
5. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990;50:6823-6826.
6. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
7. Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG: Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995;13:227-232.
8. Moertel CG, Childs DS Jr., Reitemeier RJ, Colby MY Jr, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;ii:865-867.
9. Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE: Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988;14:79-84.
10. Ren Q, Kao V, Grem JL: Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998;4:2811-2818.
11. Min YJ, Joo KR, Park NH, Yun TK, Nah YW, Nam CW, Park JH: Gemcitabine therapy in patients with advanced pancreatic cancer. Korean J Intern Med 2002;17:259-262.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
13. Sporn JR: Practical recommendations for the management of adenocarcinoma of the pancreas. Drugs 1999;57:69-79.
14. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996;23:220-228.
15. Permert J, Hafstrom L, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 2001;40:361-370.
16. Oztop I, Yilmaz U, Yavuzsen T, Yaren A, Tarhan O, Sagol O, Coker A, Alakavuklar M: Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy 2004;50:127-132.
17. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-885.
18. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
19. Crino L, Mosconi AM, Calandri C, Corgna E, Porrozzi S, Chiara S, Nobili MT, Tonato M: Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol 2001;24:296-298.
20. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine: results for over 3,000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
21. Noble S, Goa KL: Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-472.
22. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-2736.
23. Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, Minckwitz GV, Mansouri K, Blatter J, Breitbach GP: Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer 2003;13:130-137.
24. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, Garcia M, Lianes P, Montalar J, Vadell C, Gonzalez-Larriba JL, Nguyen B, Artal A, Rosell R: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
25. Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-4031.
26. Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M: Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005;104:1237-1245.
27. Tanno S, Nakano Y, Osanai M, Koizumi K, Izawa T, Habiro A, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Kohgo Y: A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer. Chemotherapy 2006;52:98-102.
28. Furuse J, Ishii H, Okusaka T, Nagase M, Nakachi K, Ueno H, Ikeda M, Morizane C, Yoshino M: Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. Jpn J Clin Oncol 2005;35:733-738.
29. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Köhler K, Stauch M, Oettle H; Deutsche Krebsgesellschaft: A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2005;23:310S.
30. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, Schueller J, Bernhard J, Dietrich D, Scheithauer W: Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 2005;23:310S.
31. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Ding K, Christy-Bittel J, Parulekar W: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) Proc Am Soc Clin Oncol 2005;23:1S.